{"preliminary_commentary":{"by_channel":{"x_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["niraparib","abiraterone","leuprolide"]],"indication":"high-risk and node-positive prostate cancer","name":"ASCLEPIuS","nct_id":"NCT04194554","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=asclepius-nct04194554. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ASCLEPIuS","arms":[{"description":"Dose Level 1: 100 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT\n\nDose Level 2: 200 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT\n\nDose Level 3: 200 mg PO daily of Niraparib without breaks during SBRT until completion of 6 cycles.","label":"Niraparid Dose Escalation","type":"EXPERIMENTAL"}],"collaborators":["Janssen Scientific Affairs, LLC"],"completion_date":{"date":"2029-05","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":102,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Niraparib","otherNames":[],"type":"DRUG"},{"name":"Leuprolide","otherNames":[],"type":"DRUG"},{"name":"Abiraterone Acetate","otherNames":[],"type":"DRUG"},{"name":"Stereotactic body radiotherapy (SBRT)","otherNames":["Ultra-hypofractionated radiotherapy"],"type":"RADIATION"}],"last_update":"2026-05-01","lead_sponsor":"University of Michigan Rogel Cancer Center","official_title":"A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose-limiting toxicities (Phase 1)","timeFrame":"Up to 112 days after initial dose of niraparib"},{"measure":"Proportion of patients experiencing biochemical failure","timeFrame":"Up to 3 years after first dose of niraparib"}],"references":[],"start_date":{"date":"2020-11-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04194554"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/asclepius-nct04194554"}